- Alnylam to discuss Huntington’s disease program at October 26 RNAi Roundtable - CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics ...
Below is a list of sell-side analysts actively covering Alnylam ...
Feb 15, 2024 Feb 15, 2024 − Achieved Fourth Quarter and Full Year 2023 Global Net Product Revenues of $346 Million and $1,241 Million, Respectively, Representing 39% Annual Growth Compared to 2022 – − ...
– Qfitlia Becomes the Sixth Alnylam-Discovered RNAi Therapeutic Approved by U.S. FDA and First and Only to Treat Hemophilia A or B With or Without Inhibitors – ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 30, 2026-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new data at the European Society of Cardiology ...
Alnylam Pharmaceuticals Reports Third Quarter 2021 Financial Results and Highlights Recent Period Activity Oct 28, 2021 − Achieved Third Quarter 2021 Combined Net Product Revenues of $167 Million for ...
Net product revenues increased 35% during the third quarter 2023, as compared to the prior year, and 33% at CER. The increase is primarily related to growth in our TTR product revenues driven by the ...
Net product revenues increased 32% and 35% at actual currency during the three and twelve months ended December 31, 2022, respectively, compared to the same periods in 2021, and 41% and 43% at CER, ...
– Launching on World Heart Day, Retired Professional Football Player Pete Shaw Shares How Symptoms Attributed to Football and Aging Led to a Delayed ATTR-CM Diagnosis – – ‘Play by Play’ Uses Sports to ...
– At 9 Months, Vutrisiran Met Primary and All Secondary Endpoints, with Statistically Significant Improvements in Neuropathy, Quality of Life (QoL), and Gait Speed, Relative to Placebo – – In Majority ...
− Presents Pre-clinical Data with IKARIA Platform Demonstrating Potential to Achieve Over 90% Target Knockdown with an Annual Dosing Regimen – “At OTS this year we are pleased to share research ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results